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ABSTRACT
Introduction: Methadone is a full agonist of
the opioid receptor mu 1 which is encoded by
the OPRM1 gene. Sleep disorders were
frequently reported by opioid-dependent
patients during methadone maintenance
therapy (MMT). It is possible, therefore, that
genetic polymorphisms in OPRM1 influence
sleep quality among patients on MMT. This
study investigated the association of OPRM1
polymorphisms with sleep quality among
opioid-dependent patients on MMT.
Methods: The sleep quality of 165 male
opioid-dependent patients receiving MMT was
evaluated using the Pittsburgh Sleep Quality
Index (PSQI). DNA was extracted from whole
blood and subjected to polymerase chain
reaction (PCR) genotyping.
Results: Patients with IVS2 ? 691 CC genotype
had higher PSQI scores [mean (SD) = 5.73
(2.89)] compared to those without the
IVS2 ? 691 CC genotype (IVS2 ? 691 GG/GC
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genotype) [4.92 (2.31)], but the difference did
not reach statistical significance (p = 0.081).
Patients with combined 118 AA genotype and
IVS2 ? 691 GC genotype (AC/AG diplotype)
had significantly lower PSQI scores [mean
(SD) = 4.25 (2.27)] compared to those without
the diplotype [5.68 (2.77)] (p = 0.018).
Conclusion: Our study indicates that the AC/
AG diplotype for the 118A[G and
IVS2 ? 691G[C polymorphisms of OPRM1
gene is associated with better sleep quality
among males with opioid dependence on MMT.
Keywords: AC/AG diplotype; Male patients;
Methadone; Methadone maintenance therapy;
Opioid dependence; Opioid receptor; Opioid
receptor, mu 1 gene; OPRM1; Pittsburgh Sleep
Quality Index; Sleep quality
INTRODUCTION
Sleep disorders were frequently reported by
opioid-dependent patients during methadone
maintenance therapy (MMT) [1–6]. Patients on
MMT demonstrated disrupted sleep including
increased stage 2 sleep and decreased REM sleep
and stage 1 sleep compared to age, sex, and
body mass index (BMI) matched normal
subjects [7]. In addition, they reported
significantly worse daytime function, were
more depressed, and had increased daytime
sleepiness when compared to the control
subjects [8]. The sleep disturbances among
opioid-dependent patients on MMT
contributed to premature exit from treatment
[9–11], increased use of medications (prescribed
or ‘‘over the counter’’) to help with sleep [1–3],
and increase in chronic depressive symptoms [8,
12]. The sleep disturbances also impacted on
quality of life and could impair engagement
with treatment leading to continued drug use
[1, 5, 12].
Previous studies showed that opioids affected
sleep by acting on both sleep- and
wake-promoting systems at the pontine
reticular formation (PRF) and the substantia
innominata within the basal forebrain (BF) [13].
In the PRF, the administration of opioids
decreased adenosine levels and this was
dependent upon opioid receptor, mu 1 gene
(OPRM1) agonism, and subsequently resulted in
sleep disturbance-related side effects of opioids
[14].
Opioid drugs, including morphine, fentanyl,
and methadone, are agonists of the l-opioid
receptor which is encoded by the OPRM1 gene.
It has been suggested that the efficacy and side
effects of commonly used opioids are associated
with their affinity for l-opioid receptor. Some of
the OPRM1 polymorphisms that affect the
density and function and consequently the
signaling efficacy of l-opioid receptors may
contribute to interindividual variations in the
response to opioids [15–17]. 118A[G (dbSNP
rs1799971, Asn40Asp) polymorphism is one of
the most frequently studied polymorphisms of
OPRM1. It is found in exon 1 and may greatly
affect the l-opioid receptor N-glycosylation and
reduced stability of the receptor in cell cultures
[18]. N-Glycosylation plays a part in many
cellular processes like receptor folding, sorting,
expression, and ligand binding. IVS2 ? 691G[C
(dbSNP rs2075572) polymorphism at 691 bp
downstream of exon 2 is located within
intron 2 [19–21]. The polymorphism might
change the regulation of the expression of
OPRM1 gene and might also cause formation
of different isoforms of human l-opioid
receptor [20, 22].
A few studies have reported on the
association between methadone treatment and
OPRM1 polymorphisms [23–27]. Thus far, one
study explored if the OPRM1 polymorphisms
could provide a possible explanation for the
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noted sleep problems of opioid-addicted
individuals [24]; unfortunately the role of the
OPRM1 individual’s pair of haplotypes
(diplotype) remains uncertain because they did
not consider analysis of OPRM1 diplotype.
Recently, we published our data on the more
clinically important aspects of pain sensitivity
[28]. We felt that it is also necessary to report
our findings on the relationship between sleep
quality and opioid genetic polymorphisms.
Thus, in the present paper, our aim was to
investigate sleep quality as sleep disorders were
frequently reported by opioid-dependent
patients during MMT. A better understanding
of the role of OPRM1 polymorphisms in sleep
disturbance-related side effects of opioids has
implications for the treatment of sleep and
addictive disease, and clinical management of
each in the presence of the other. To help
resolve this we aimed to investigate the
influence of OPRM1 polymorphisms on sleep




Opioid-dependent patients who had been
diagnosed according to Diagnostic and
Statistical Manual of Mental Disorders, Fourth
Edition (DSM-IV) criteria [29] and were
attending the national MMT programme at
the Hospital Universiti Sains Malaysia and
other MMT clinics in Kota Bharu, Pasir Mas,
Pasir Puteh and Bachok, Kelantan, Malaysia
during the study period were screened and
invited to participate in the study. In this
study, we included only men as this reflects
the cohort population of drug abusers in
Malaysia where more than 90% of them are
male [30].
Inclusion criteria were (a) men aged more
than 18 years; (b) those stabilized in treatment,
defined as having been enrolled in the MMT
programme for more than 1 month; (c) patients
with two consecutive negative urine tests
1 week prior to the study; (d) free from acute
medical, surgical, and psychiatric illnesses;
(e) free from regular use of alcohol; and (f) free
from drug intoxication. The exclusion criteria
were (a) individuals with major psychiatric
illnesses such as schizophrenia; (b) individuals
who were currently illicitly taking
benzodiazepines, cannabinoids, and
barbiturates; (c) individuals on regular
anticonvulsants, neuroleptics, or analgesics;
(d) individuals with chronic or ongoing acute
pain; (e) individuals with a history of analgesics
ingestion within 3 days before the study; and
(f) individuals with severe cognitive impairment
which may interfere with sleep assessments
and/or communication.
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1964, as revised in
2013. Written informed consent was obtained
from each subject after a complete description
of the study. The study was approved by the
Human Research Ethics Committee (HREC),
Universiti Sains Malaysia (USM) in Kelantan,
Malaysia (reference number USMKK/PPP/JEPeM
(253.3 [14])) and the Medical Research and
Ethics Committee (MREC) at the Ministry of
Health (MOH), Malaysia (reference number
NMRR-13-524-16614).
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Assessment of Sleep Quality Using Malay
Version of the Pittsburgh Sleep Quality
Index (PSQI-M)
Patients were asked to fill out the Malay version
of the Pittsburgh Sleep Quality Index (PSQI–M).
The PSQI is a validated questionnaire to
measure subjective sleep quality and
disturbances during the previous month and it
has been translated into several languages
including Malay. The PSQI has been
successfully used in patients with opioid
dependence receiving MMT among ethnically
different populations [1–4, 6, 8, 31–38]. The 19
individual items are used to generate seven
component scores: subjective sleep quality (one
item), sleep latency (two items), sleep duration
(one item), habitual sleep efficiency (three
items), sleep disturbances (nine items), use of
sleep medications (one item), and daytime
dysfunction (two items). Each of the seven
component scores is determined on the basis
of scoring guidelines, with the seven
component scores each with a potential range
of 0–3, where 3 reflects the negative extreme on
the Likert scale. The sum of these seven
component scores yields one global score of
subjective sleep quality with a potential range
of 0–21, with higher scores representing poorer
subjective sleep quality [39].
Genotyping Methods for OPRM1
Polymorphisms
Genomic DNA was extracted from whole blood
by use of the QIAamp DNA Blood Mini Kit
(Qiagen GmbH, Hilden, Germany). OPRM1
polymorphisms [118A[G (dbSNP rs1799971)
and IVS2 ? 691G[C (dbSNP rs2075572)] were
determined by use of an allele-specific
multiplex polymerase chain reaction (PCR)
method [28, 40]. All reactions were performed
on the Applied Biosystems Veriti 96-Well
Thermal Cycler (Applied Biosystems, USA). A
complete PCR method is available upon
request.
Statistical Analysis
The population genetic data analytical program
Golden Helix SNP and Variation Suite 7 (SVS 7,
version 7.3.1; Golden Helix Inc., Bozeman, MT,
USA) was used to apply the
expectation–maximization (EM) algorithm to
construct OPRM1 haplotypes and diplotypes.
The sum of seven component scores of PSQI was
calculated as the global score for sleep quality.
Independent t test and one-way ANOVA test
were used to compare PSQI scores (i.e.,
continuous variable) [1, 6] between OPRM1
polymorphisms (118A[G and IVS2 ? 691G[C)
according to their genotypes and allelic additive
models, genotype dominant and recessive
models, haplotypes and diplotypes where
appropriate (frequencies less than 10.0% were
pooled). Data analyses were done after all
genotyping of the patients was completed.
Statistical analysis was carried out using SPSS/
Win software (Version 22, SPSS, Inc., Chicago,
IL, USA). Correction for multiple testing was
not performed since only one gene was tested
[41]. A p value less than 0.05 was considered
significant.
RESULTS
Characteristics of Study Participants
A total of 165 opioid-dependent patients
fulfilled inclusion and exclusion criteria, gave
informed consent, and completed the study.
Patients’ mean age was 37.27 years [standard
deviation (SD) 6.24, range 25–55]. The mean
duration in the MMT program was 2.92 years
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(SD 2.09, range 0.33–9.00). The mean daily
methadone dose was 76.64 mg/day (SD 37.63,
range 20–360). The mean PSQI score was 5.47
(SD 2.74, range 0–14), slightly above a cutoff
score of 5, thus indicating poor overall sleep
quality [39]. Specifically, 58.8% (N = 97) of
patients had PSQI scores greater than 5,
indicating they were ‘poor sleepers’.
OPRM1 Polymorphisms
The observed allelic frequencies were 40.6% for
118G and 83.9% for IVS2 ? 691C. The
combination of the individual polymorphisms
into OPRM1 haplotype pairs revealed the
presence of seven diplotypes. The most
common haplotype pair was AC/GC (N = 56,
33.9%), followed by AC/AC (N = 34, 20.6%) and
AC/AG (N = 24, 14.5%).
Association of OPRM1 Polymorphisms
with PSQI Scores
Table 1 shows that patients with homozygous
118 AA genotype had lower PSQI scores
compared to those without 118 AA genotype
(118 AG/GG genotype) (5.28 vs 5.58), but the
difference did not quite reach statistical
significance (p = 0.499).
Patients with the heterozygous GC genotype
had the lowest PSQI scores among the three
IVS2 ? 691G[C genotypes (Table 1). Patients
with the homozygous CC genotype had higher
PSQI scores when compared to those without
the IVS2 ? 691 CC genotype (IVS2 ? 691 GG/
GC genotype) (5.73 vs 4.92), but the difference
did not reach statistical significance (p = 0.081).
In view of this, we performed diplotype
analysis constructed from the two OPRM1
polymorphisms (118A[G and IVS2 ? 691G[C)
and found a significant difference between
patients with combined homozygous 118 AA
genotype and heterozygous IVS2 ? 691 GC
genotype (AC/AG diplotype) and those
without this diplotype (p = 0.018). Patients
with the AC/AG diplotype had significantly
lower PSQI scores when compared with those
without the diplotype (4.25 vs 5.68).
DISCUSSION
Previous association studies have produced
mixed results regarding OPRM1
polymorphisms and methadone treatment
efficacy, and side effects included changes in
libido and insomnia [24], in MMT response
status in terms of illicit opioid use detection in
random urinalysis [25], in apparent
susceptibility to methadone poisoning [26,
27], and in both pain responses and opioid
addiction [23]. Among studies that focused on
genetic polymorphisms related to
pharmacodynamics of methadone, only one
study investigated the association between the
noted sleep problems of opioid-addicted
individuals and polymorphisms in gene
coding for the OPRM1 [24]; unfortunately the
role of the OPRM1 individual’s pair of
haplotypes (diplotype) remains uncertain
because they did not consider analysis of
OPRM1 diplotypes.
Previously, Wang et al. [24] found that the
insomnia side effect was significantly higher in
patients with IVS2? 691 CC genotype than
those without the genotype (IVS2? 691 GG/GC
genotype). Their results suggested that
IVS2? 691G[C polymorphism may participate
in the regulation of the function of the OPRM1.
Interestingly, in the current study, PSQI scores
were 16.3% higher in patients with homozygous
IVS2? 691 CC genotype than those without the
genotype (IVS2? 691 GG/GC genotype);
however, our results were statistically
insignificant (p = 0.081). Additionally, when the
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Table 1 Association between 118A[G and IVS2 ? 691G[C polymorphisms and PSQI scores in opioid-dependent
patients
Polymorphism Number Percent Mean SD Test statistic (df) p valuec
118A[G
Genotype (N = 165)
AA 58 35.2 5.28 2.83 0.36 (2, 162)a 0.698
AG 80 48.5 5.50 2.71
GG 27 16.4 5.81 2.70
Allele (N = 330)
A 196 59.4 5.37 2.77 -0.85 (328)b 0.399
G 134 40.6 5.63 2.69
Dominant model
AA 58 35.2 5.28 2.83 -0.68 (163)b 0.499
AG ? GG 107 64.8 5.58 2.70
Recessive model
AA ? AG 138 83.6 5.41 2.75 -0.71 (163)b 0.480
GG 27 16.4 5.81 2.70
IVS2 ? 691G[C
Genotype (N = 165)
GG 1 0.6 9.00 – 2.71 (2, 162)a 0.070
GC 51 30.9 4.84 2.26
CC 113 68.5 5.73 2.89
Allele (N = 330)
G 53 16.1 5.00 2.35 -1.37 (328)b 0.170
C 277 83.9 5.56 2.80
Dominant model
GG 1 0.6 9.00 – 1.29 (163)b 0.198
GC ? CC 164 99.4 5.45 2.74
Recessive model
GG ? GC 52 31.5 4.92 2.31 -1.76 (163)b 0.081
CC 113 68.5 5.73 2.89
Haplotype (N = 330)d
AC 148 44.8 5.51 2.89 0.76 (3, 326)a 0.518
GC 129 39.1 5.63 2.70
AG 48 14.5 4.94 2.34
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Table 1 continued
Polymorphism Number Percent Mean SD Test statistic (df) p valuec
GG 5 1.5 5.60 2.70
AC 148 44.8 5.51 2.89 1.01 (2, 327)a 0.366
GC 129 39.1 5.63 2.70
Combined AG and GG 53 16.1 5.00 2.35
AC 148 44.8 5.51 2.89 0.20 (328)b 0.839
Not AC 182 55.2 5.45 2.62
GC 129 39.1 5.63 2.70 0.82 (328)b 0.410
Not GC 201 60.9 5.37 2.76
AG 48 14.5 4.94 2.34 -1.47 (328)b 0.143
Not AG 282 85.5 5.56 2.79
Diplotype (N = 165)
AC/GC 56 33.9 5.45 2.91 1.40 (5, 159)a 0.229
AC/AC 34 20.6 6.00 2.98
AC/AG 24 14.5 4.25 2.27
GC/AG 23 13.9 5.48 2.17
GC/GC 23 13.9 6.00 2.78
Otherse 5 3.0 5.60 2.70
AC/GC 56 33.9 5.45 2.91 -0.09 (163)b 0.930
Not AC/GC 109 66.1 5.49 2.67
AC/AC 34 20.6 6.00 2.98 1.26 (163)b 0.209
Not AC/AC 131 79.4 5.34 2.67
AC/AG 24 14.5 4.25 2.27 -2.40 (163)b 0.018
Not AC/AG 141 85.5 5.68 2.77
GC/AG 23 13.9 5.48 2.17 0.01 (163)b 0.992
Not GC/AG 142 86.1 5.47 2.83
GC/GC 23 13.9 6.00 2.78 0.99 (163)b 0.322
Not GC/GC 142 86.1 5.39 2.74
N number of subject/allele/haplotype/diplotype, SD standard deviation
a t statistic using independent t test
b F statistic using one-way ANOVA test
c p value is signiﬁcant at\0.05
d Haplotype patterns were constructed from the two OPRM1 polymorphisms (118A[G and IVS2 ? 691G[C)
e Diplotype with frequency less than 10.0 % was pooled under ‘others’ (and included AG/GG and GC/GG)
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PSQI scores were compared using the diplotype
approach, we found that patients with combined
118 AA genotype and IVS2? 691 GC genotype
(AC/AG diplotype) had 25.2% significantly lower
PSQI scores compared to those without the
diplotype. To the best of our knowledge, data
on the influence of theOPRM1 diplotype on sleep
quality among opioid-dependent patients is not
available for reference. However, this finding
suggested that opioid-related adverse effects such
as sleep problems were less likely to occur in
patients with AC/AG diplotype at 118 and
IVS2? 691 in OPRM1, given that a mechanism
of opioid-induced adverse events involves
OPRM1. Hence, results of the current study
support the suggestion by Wang et al. [24] that
the OPRM1 gene and its transcript isoforms may
be involved in the underlying cause of insomnia.
The exact molecular mechanism regarding
the effects of AC/AG diplotype on the sleep
quality is unclear. However, it is well established
that, in general, the function of the OPRM1 is
under the influence OPRM1 gene
polymorphisms [19–21]. The IVS2 ? 691G[C
polymorphism is predicted to change the
affinity of transcriptional regulatory factors for
the intronic DNA sequence and directly alter
mRNA levels, and therefore it might change the
regulation ofOPRM1 gene expression. It was also
shown that the DNA intronic sequence can be
involved in alternativeDNA splicing, resulting in
different isoforms of human OPRM1 [20, 22].
On the basis of our results, we suggest that
strong linkage disequilibrium (LD) between
these polymorphisms and other unstudied
polymorphisms [42, 43] formed a series of
diplotypes which may affect OPRM1
expression or function (or both) at the site of
its action in the brain and resulted in altered
binding affinity between endogenous (and/or
exogenous) opioid agents and the OPRM1, and
hence diplotype differences may contribute to
interindividual differences in sleep-disrupting
effects of opioids.
Available data indicates that opioids affect
sleep by acting on both sleep- and
wake-promoting systems at the pontine
reticular formation (PRF) and the substantia
innominata within the basal forebrain (BF) [13].
Opioids decreased adenosine levels in the PRF
and this is dependent upon OPRM1 agonism,
and subsequently resulted in sleep
disturbance-related side effects of opioids [14].
Our results support the hypothesis that patients
with AC/AG diplotype had a higher ability to
prevent opioid-induced decreases in adenosine
and therefore resulted in lower susceptibility to
sleep disturbances.
Some limitations to this study need to be
highlighted. In our current study, we excluded
patients with psychiatric illnesses such as
schizophrenia, depression, and anxiety that
are commonly associated with sleep disorder;
the presence of these illnesses would be
expected to increase the severity of sleep
problems in our study subjects. Interestingly,
although known psychiatric illnesses were one
of our exclusion criteria, no participants were
excluded because of this criterion. Non-genetic
sleep-related factors among patients on MMT
were not reported because the focus of the
current manuscript was to look into
pharmacogenetics factors associated with
susceptibility to opioid-induced sleep
disturbance among opioid-dependent patients
on opioid maintenance therapy.
Patients without the AC/AG diplotype
(N = 141, 85.5%) had a mean PSQI score of
5.68 (SD 2.77), slightly above a cutoff score of 5,
thus indicating poor overall sleep quality
among them [39]. We suggest that sleep
disorders should be evaluated and treated
among MMT patients, particularly in those
without the AC/AG diplotype. Patients with
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sleep disorders tend to self-medicate to promote
sleep or to stay awake during the day [44]. Many
of these patients may be at risk of significant
drug–drug interactions resulting in ineffective
treatment and enhanced side effects of the
drugs which could have a profound impact on
quality of life, health, and even could impair
engagement with treatment leading to
continued drug use [1, 5, 12].
Further studies are needed to study other
OPRM1 polymorphisms and genetic variations
of other sleep-related genes and genes related to
pharmacokinetics and pharmacodynamics of
methadone, and to obtain data on
endogenous adenosine concentration and data
on the functional effects of AC/AG diplotype on
OPRM1 expression or function in the brain.
CONCLUSION
Our study indicates that the AC/AGdiplotype for
the118A[GandIVS2 ? 691G[Cpolymorphisms
of OPRM1 gene is associated with better sleep
quality among opioid-dependent patients on
MMT. The results of this study lead to a better
understanding of the pharmacogenetics factors
associated with susceptibility to opioid-induced
sleep disturbance in this population. Therefore,
determining which diplotyes may increase
susceptibility to sleep disturbance-related side
effects of methadone could be important.
Personalised medicine based on
pharmacogenetics may be able to improve the
effectiveness of methadone and reduce its side
effects.
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